AOD 9604 benefits

AOD 9604 was engineered to isolate the fat-burning activity of human growth hormone from everything else hGH does. Here's the mechanism, the preclinical data that got it into human trials, and an honest look at which benefits are supported by evidence versus marketing.

What AOD 9604 was designed to do

AOD 9604 — short for "Anti-Obesity Drug 9604" — is one of the cleanest examples of rational peptide engineering aimed at a single metabolic effect. Researchers at Monash University in Australia, led by Professor Frank Ng, had identified that the fat-mobilizing activity of human growth hormone was localized to the C-terminal region of the molecule. Full-length hGH is a 191-amino-acid protein with broad effects: it raises IGF-1, drives linear growth, and — at pharmacological doses — promotes insulin resistance. Those effects make it a poor fit for an obesity drug even though its lipolytic activity is well established.

AOD 9604's core benefit, then, is selectivity. By using only amino acids 176–191 of the hGH sequence, the peptide retains the fat-burning signal while dropping the hypertrophic and diabetogenic ones. That is the entire premise of the molecule, and it is the lens through which every claimed benefit should be evaluated.

Mechanism of action: how AOD 9604 works

AOD 9604 exerts its effects primarily on adipose tissue through two mechanisms:

• Stimulating lipolysis. The peptide increases the breakdown of stored triglycerides into free fatty acids and glycerol. Preclinical work suggests this is mediated through beta-3 adrenergic receptor pathways and increased expression of hormone-sensitive lipase in fat cells.
• Inhibiting lipogenesis. AOD 9604 suppresses the conversion of non-fat substrates (primarily glucose and amino acids) into new triglycerides, reducing the rate at which adipocytes can replenish fat stores.

The net effect in animal models is a reduction in total fat mass — particularly visceral fat — without a meaningful change in lean body mass or food intake. That profile is what made AOD 9604 attractive as an oral anti-obesity candidate: the drug reduces fat through metabolic action rather than appetite suppression, which is the opposite mechanism from GLP-1 agonists like semaglutide and tirzepatide.

AOD 9604 benefits supported by preclinical data

Published animal studies and the Metabolic Pharmaceuticals program established the following effects in obese rodents and early-phase human volunteers:

1. Reduced total body fat. Obese mice given AOD 9604 lost significantly more body fat than controls over 14- and 19-day studies, with effects concentrated in adipose depots.
2. Preserved lean mass. No loss of skeletal muscle or organ mass was observed — a practical advantage over calorie-restriction-based weight loss, which typically depletes lean tissue along with fat.
3. No rise in IGF-1. In human pharmacokinetic studies, AOD 9604 did not elevate serum IGF-1, confirming the molecule's separation from the growth-promoting arm of hGH.
4. No acute impact on glucose or insulin. Short-term dosing did not produce the insulin resistance or glucose intolerance seen with supraphysiologic hGH administration.
5. Good tolerability at high oral doses. Oral doses up to 54 mg/day were tested in Phase II without dose-limiting toxicity — though efficacy at those doses was also limited (see the weight loss page).

Claimed benefits that are not well supported

In the years after Metabolic Pharmaceuticals wound down its obesity program, AOD 9604 was repurposed in compounding pharmacies and peptide-user communities for a range of off-label indications. Several of these claims circulate widely but are not supported by published human trials.

AOD 9604 peptide benefits in context

The honest summary is this: AOD 9604 has a clean, specific, and scientifically interesting mechanism, but its clinical benefits as an obesity drug were modest. The Phase IIb trial in 2007 did not hit its primary endpoint of clinically significant weight loss versus placebo, which is why Metabolic Pharmaceuticals did not advance the molecule into Phase III. Animal models remain the strongest source of evidence for the fat-loss effect.

For a comparison with the drugs that did succeed commercially in the obesity space — GLP-1 agonists like semaglutide and dual GIP/GLP-1 agonists like tirzepatide — see the AOD 9604 vs semaglutide and AOD 9604 vs tirzepatide comparison pages.

Frequently asked questions